CPHI
Income statement / Annual
Last year (2023), China Pharma Holdings, Inc.'s total revenue was $7.01 M,
a decrease of 13.48% from the previous year.
In 2023, China Pharma Holdings, Inc.'s net income was -$3.08 M.
See China Pharma Holdings, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$7.01 M
|
$8.10 M
|
$9.64 M
|
$10.87 M
|
$10.92 M
|
$12.33 M
|
$13.21 M
|
$15.57 M
|
$20.35 M
|
$22.13 M
|
| Cost of Revenue |
$7.52 M |
$8.60 M |
$9.29 M |
$8.91 M |
$9.44 M |
$10.36 M |
$10.74 M |
$12.35 M |
$18.89 M |
$19.47 M |
| Gross Profit |
-$504,881.00 |
-$493,916.00 |
$349,270.00 |
$1.95 M |
$1.48 M |
$1.97 M |
$2.47 M |
$3.22 M |
$1.46 M |
$2.67 M |
| Gross Profit Ratio |
-0.07 |
-0.06 |
0.04 |
0.18 |
0.14 |
0.16 |
0.19 |
0.21 |
0.07 |
0.12 |
| Research and Development
Expenses |
$240,080.00
|
$185,858.00
|
$318,964.00
|
$377,964.00
|
$229,637.00
|
$172,384.00
|
$90,474.00
|
$365,969.00
|
$961,897.00
|
$2.80 M
|
| General & Administrative
Expenses |
$1.47 M
|
$1.89 M
|
$1.65 M
|
$1.82 M
|
$2.29 M
|
$1.95 M
|
$2.02 M
|
$2.27 M
|
$1.90 M
|
$1.72 M
|
| Selling & Marketing
Expenses |
$780,328.00
|
$1.07 M
|
$1.50 M
|
$2.22 M
|
$2.35 M
|
$3.22 M
|
$3.46 M
|
$4.04 M
|
$4.29 M
|
$3.35 M
|
| Selling, General &
Administrative Expenses |
$2.25 M
|
$2.87 M
|
$3.15 M
|
$4.04 M
|
$4.64 M
|
$5.77 M
|
$6.87 M
|
$7.39 M
|
$16.34 M
|
$36.42 M
|
| Other Expenses |
$0.00 |
$93,851.00 |
$0.00 |
$115.19 B |
$7.58 T |
$0.00 |
$4.83 T |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$2.25 M |
$3.15 M |
$3.46 M |
$4.42 M |
$4.87 M |
-$12.42 M |
-$21.15 M |
-$11.37 M |
-$15.76 M |
-$41.43 M |
| Cost And Expenses |
$9.76 M |
$5.54 M |
$12.76 M |
$13.33 M |
$14.31 M |
-$2.07 M |
-$10.40 M |
$978,027.00 |
$3.12 M |
-$21.96 M |
| Interest Income |
$6,602.00 |
$10,755.00 |
$3,035.00 |
$5,675.00 |
$27,527.00 |
$38,516.00 |
$64,414.00 |
$130,575.00 |
$119,925.00 |
$69,739.00 |
| Interest Expense |
$333,600.00 |
$434,619.00 |
$542,001.00 |
$294,159.00 |
$321,718.00 |
$451,258.00 |
$539,334.00 |
$849,557.00 |
$1.17 M |
$785,804.00 |
| Depreciation &
Amortization |
$2.75 M
|
$2.70 M
|
$3.09 M
|
$2.68 M
|
$2.93 M
|
$3.26 M
|
$3.29 M
|
$3.08 M
|
-$3.60 M
|
-$1.79 M
|
| EBITDA |
$8,436.00
|
-$837,689.00
|
$230,345.00
|
$106,852.00
|
-$17.45 M
|
-$7.15 M
|
-$15.32 M
|
-$4.95 M
|
-$10.58 M
|
-$36.90 M
|
| EBITDA Ratio |
0 |
-0.1 |
-0 |
0.02 |
-0.04 |
-0.06 |
-0.09 |
-0.07 |
-0.52 |
-1.57 |
| Operating Income Ratio
|
-0.39
|
-0.44
|
-0.32
|
-0.23
|
-0.31
|
-0.32
|
-0.34
|
-0.27
|
-0.7
|
-1.65
|
| Total Other
Income/Expenses Net |
-$326,998.00
|
-$423,864.00
|
-$538,966.00
|
-$288,484.00
|
-$17.31 M
|
-$6.89 M
|
-$14.66 M
|
-$4.68 M
|
-$1.15 M
|
-$2.93 M
|
| Income Before Tax |
-$3.08 M |
-$3.97 M |
-$3.40 M |
-$2.87 M |
-$20.70 M |
-$10.86 M |
-$19.15 M |
-$8.87 M |
-$15.35 M |
-$39.47 M |
| Income Before Tax Ratio
|
-0.44
|
-0.49
|
-0.35
|
-0.26
|
-1.9
|
-0.88
|
-1.45
|
-0.57
|
-0.75
|
-1.78
|
| Income Tax Expense |
$0.00 |
$6.25 M |
$542,001.00 |
$294,159.00 |
$321,718.00 |
$109,989.00 |
$122,631.00 |
$308,175.00 |
$60,439.00 |
$77,042.00 |
| Net Income |
-$3.08 M |
-$10.22 M |
-$3.94 M |
-$3.16 M |
-$21.02 M |
-$10.75 M |
-$19.28 M |
-$9.18 M |
-$15.41 M |
-$26.05 M |
| Net Income Ratio |
-0.44 |
-1.26 |
-0.41 |
-0.29 |
-1.92 |
-0.87 |
-1.46 |
-0.59 |
-0.76 |
-1.18 |
| EPS |
-0.91 |
-1.94 |
-0.85 |
-0.72 |
-4.82 |
-2.47 |
-4.42 |
-2.11 |
-3.54 |
-5.99 |
| EPS Diluted |
-0.91 |
-1.94 |
-0.85 |
-0.72 |
-4.82 |
-2.47 |
-4.42 |
-2.11 |
-3.54 |
-5.98 |
| Weighted Average Shares
Out |
$3.38 M
|
$5.26 M
|
$4.61 M
|
$4.36 M
|
$4.36 M
|
$4.36 M
|
$4.36 M
|
$4.36 M
|
$4.36 M
|
$4.35 M
|
| Weighted Average Shares
Out Diluted |
$3.38 M
|
$5.26 M
|
$4.61 M
|
$4.36 M
|
$4.36 M
|
$4.36 M
|
$4.36 M
|
$4.36 M
|
$4.36 M
|
$4.36 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
